The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAFV600-positive melanoma: Interim analysis of the ImmunoCobiVem study.
 
Dirk Schadendorf
Honoraria - 4SC; Amgen; Array BioPharma; Bristol-Myers Squibb; Daiichi Sankyo Japan; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; Nektar; NeraCare GmbH; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi/Regeneron; Sun Pharma; Ultimovacs
Consulting or Advisory Role - 4SC; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; NEKTAR; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Helen Gogas
Honoraria - Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Sanofi/Regeneron
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Pfizer
 
Lidija Kandolf Sekulovic
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; MSD Oncology; Novartis; Roche
Speakers' Bureau - Abbvie; Bristol-Myers Squibb; Janssen; MSD Oncology; Novartis; Roche
Travel, Accommodations, Expenses - MSD Oncology; Roche
 
Friedegund Elke Meier
Honoraria - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Roche; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Research Funding - Novartis; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
 
Thomas Eigentler
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Novartis; Pierre Fabre; Sanofi/Regeneron
Speakers' Bureau - Almirall Hermal GmbH
 
Jan-Christoph Simon
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Research Funding - Novartis
 
Patrick Andres Maximilian Terheyden
Honoraria - Bristol-Myers Squibb; CureVac; Merck Serono; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - 4SC; Almirall; Bristol-Myers Squibb; Merck KGaA; Novartis; Pierre Fabre; Roche; Sanofi
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pierre Fabre
 
Anja Heike Gesierich
Honoraria - Almirall Hermal GmbH; MSD Sharp & Dohme GmbH; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - Novartis; Pierre Fabre
 
Rudolf Alexander Herbst
Employment - Helios Kliniken
 
Katharina C. Kähler
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; MSD
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Roche
 
Dimitrios C. Ziogas
No Relationships to Disclose
 
Zeljko Mijuskovic
Honoraria - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Janssen; La Roche-Posay; Lilly; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - Janssen; Lilly
 
Marlene Garzarolli
Speakers' Bureau - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Claus Garbe
Honoraria - BMS; CeCaVa; MSD Oncology; NeraCare GmbH; Novartis; Philogen; Roche/Genentech; Sanofi
Consulting or Advisory Role - BMS; CeCaVa; MSD Oncology; NeraCare GmbH; Novartis; Philogen; Roche/Genentech; Sanofi
Research Funding - BMS (Inst); NeraCare GmbH (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Alexander Roesch
Honoraria - Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis
Research Funding - Adtec; Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Roche
 
Selma Ugurel
Honoraria - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; Roche
Research Funding - Bristol-Myers Squibb (Inst); Merck Serono (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
 
Ralf Gutzmer
Honoraria - Almirall Hermal GmbH; Amgen; Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron; Sun Pharma
Consulting or Advisory Role - 4SC; Almirall Hermal GmbH; Amgen; Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi; Sun Pharma
Research Funding - Amgen (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Pierre Fabre; Roche; Sun Pharma
 
Jean-Jacques Grob
Consulting or Advisory Role - Amgen; BMS; Merck KGaA; MSD Oncology; Novartis; Philogen; Pierre fabre; Roche; Roche/Genentech; Sanofi; Sun Pharma
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - BMS; MSD Oncology; Novartis; Pierre Fabre
 
Lisa Zimmer
Stock and Other Ownership Interests - Bayer
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi; Sun Pharma
 
Elisabeth Livingstone
Honoraria - Bristol-Myers Squibb; Medac; Novartis; Pierre Fabre; Sanofi; Sun Pharma
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Medac; Pierre Fabre; Sun Pharma